title: Five days of no anticoagulation or antiplatelet therapy and NovoSeven administration in a HeartWare HVAD patient.
abstract: Postoperative bleeding is the most common complication following the implantation of ventricular assist devices. This is a case report of a HeartWare HVAD patient with intractable bleeding following chest tube insertion necessitating massive blood transfusion and multiple thoracotomies. Anticoagulation and antiplatelet therapy were discontinued and intravenous NovoSeven was administered as last resort. Bleeding ceased immediately and no pump-related issues were observed. However, thrombus formation in the right atrium and superior vena cava was detected.
authors.affiliation: Clinics for Cardiovascular Surgery Cardiology, Pneumology and Angiology, Heinrich-Heine University of Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany. diyar.saeed@med.uni-duesseldorf
authors.forename: Diyar
authors.initials: D
authors.lastname: Saeed
authors.forename: Alexander
authors.initials: A
authors.lastname: Albert
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kamiya
authors.forename: Bujar
authors.initials: B
authors.lastname: Maxhera
authors.forename: Ralf
authors.initials: R
authors.lastname: Westenfeld
authors.forename: Artur
authors.initials: A
authors.lastname: Lichtenberg
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000150:complications; D015199:Extracorporeal Membrane Oxygenation; D015942:Factor VIIa / Q000627:therapeutic use*; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019106:Postoperative Hemorrhage / Q000209:etiology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000209:etiology / Q000601:surgery*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa